A Phase 3 interventional study of NH002 (Perflutren Lipid Microspheres) Injectable Suspension in Cardiac Diseases, sponsored by Trust Bio-sonics, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Trust Bio-sonics, Inc. · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase III, prospective, multicenter, open-label, crossover study of the safety and efficacy of NH002-enhanced echocardiography in adult subjects with suboptimal images on non-contrast 2D transthoracic echocardiography with harmonic imaging within 30 days ahead of NH002 administration. The efficacy for two different modes of administration (i.e., IV bolus injection and infusion) will be evaluated independently.
2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.
This study's planned enrollment of 150 is above the median of 129 across 931 interventional studies indexed under Heart Diseases.
Browse Heart Diseases studies →Trust Bio-sonics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any evidence of other severe or unstable cardiopulmonary and/or systemic hemodynamic conditions deemed unsuitable for the study by the investigator(s) prior to NH002 dose administration, including, but not limited to:
Pregnant or lactating female. Exclude the possibility of pregnancy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who are enrolled in the study will undergo two-time resting unenhanced ultrasound examination (shortly before each dose of NH002 administration) and two-time NH002 contrast-enhanced examination on the same day at Day 1 (with the first administration via bolus injection and the second via infusion), with the standard apical 4-, 2-, and 3-chamber views obtained with B-mode and contrast-specific imaging, respectively.
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
Subjects who are enrolled in the study will undergo two-time resting unenhanced ultrasound examination (shortly before each dose of NH002 administration) and two-time NH002 contrast-enhanced examination on the same day at Day 1 (with the first administration via infusion and the second via bolus injection), with the standard apical 4-, 2-, and 3-chamber views obtained with B-mode and contrast-specific imaging, respectively.
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
Left Ventricular Endocardial Border Delineation (LVEBD)
The first primary efficacy endpoint will be the change from baseline (prior to each dose of NH002 administration) in total LVEBD scores (UEUS vs CEUS) defined using a 16-segment model derived from the standard 17-segment model, as assessed through blinded central reading. The LV endocardium of the standard apical 4-, 2-, and 3-chamber views is divided into 6 segments, with 2 basal, mid-, and apical segments in each view, of which 2 segments are shared in the standard apical 4- and 3-chamber views (i.e., a total of 16 segments in the 3 views). The 17th segment at the apex will not be scored since it does not connect to any part of the LV endocardial border. For each segment, LVEBD is graded as follows: 0 = inadequate border (border not visible); 1 = sufficient (border barely visible); 2 = good (border clearly visible). A total delineation score (0 to 32) is obtained by adding the scores from a total of the 16 segments in the 3 views.
Time frame: Image data obtained pre-injection and within 15 minutes post-injection
Left Ventricular Opacification (LVO)
The co-primary endpoint will be the proportion of subjects with adequate LVO defined by an LVO grade of +2 (moderate) or +3 (complete), as assessed through blinded central reading.
Time frame: Image data obtained pre-injection and within 15 minutes post-injection
The number and percentage of subjects with suboptimal echocardiography converted into optimal echocardiography
Objective evaluation of the number and percentage of subjects with suboptimal echocardiography (based on the definition of inadequate LVEBD, i.e., at least two segments \[in any chamber view\] with an LVEBD score of 0) converted into optimal echocardiography following administration of study drug will be summarized for each reader.
Time frame: Image data obtained pre-injection and within 15 minutes post-injection
Standard 12-lead ECGs
Standard 12-lead ECGs assessed prior to injection and at 10 and 30 minutes after the initiation of IV bolus injection and infusion; and at 24 hours after the end of the second dose of NH002
Time frame: From pre-injection (before the first dose) to 24 hours (after the end of second dose)
Blood Pressure (BP)
Change in BP assessed prior to injection and at 5, 10 and 30 minutes after the initiation of IV bolus injection and infusion; and at 24 hours after the end of the second dose of NH002
Time frame: From pre-injection (before the first dose) to 24 hours (after the end of second dose)
Heart Rate (HR)
Change in HR assessed prior to injection and at 5, 10 and 30 minutes after the initiation of IV bolus injection and infusion; and at 24 hours after the end of the second dose of NH002
Time frame: From pre-injection (before the first dose) to 24 hours (after the end of second dose)
SpO2
SpO2 assessed by pulse oximetry prior to injection and at 5, 10 and 30 minutes after the initiation of IV bolus injection and infusion; and at 24 hours after the end of the second dose of NH002
Time frame: From pre-injection (before the first dose) to 24 hours (after the end of second dose)
Physical Examination (PE)
PE assessed prior to injection and at 30 minutes after the initiation of IV bolus injection and infusion; and at 24 hours after the end of the second dose of NH002
Time frame: From pre-injection (before the first dose) to 24 hours (after the end of second dose)
Adverse Events (AEs)
AEs assessed prior to injection and at 5, 10, 15 and 30 minutes after the initiation of IV bolus injection and infusion; and at 24 hours after the end of the second dose of NH002
Time frame: From pre-injection (before the first dose) to 24 hours (after the end of second dose)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
Of 32 phase 3 interventional studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perflutren
Trust Bio-sonics, Inc.